Becton Dickinson & Co Stock Price, News & Analysis

Babson Diagnostics and BD (Becton, Dickinson and Company) have expanded their partnership to enhance blood sample collection, making it more patient-centered and less invasive. Announced on May 11, 2022, the collaboration aims to enable at-home blood sample collection and broaden test capabilities to include pediatric diagnostics. This initiative, developed since 2019, leverages advanced capillary collection technology, requiring only a fraction of the blood volume compared to traditional methods. The companies aim to improve patient compliance by providing a more convenient testing experience.

BD (Becton, Dickinson and Company) reported a revenue increase of 2.1% to $5.0 billion for Q2 FY2022, aided by a base revenue growth of 8.2%. However, COVID-only testing revenues fell to $214 million from $474 million. GAAP diluted EPS rose 59.6% to $1.50, while adjusted EPS was slightly down at $3.18. The company updated its fiscal 2022 guidance, projecting revenues between $19.6 and $19.8 billion, and adjusted EPS between $12.85 and $13.00. This reflects an increase in base business currency-neutral revenue growth estimates to 6.75%-7.75% and an anticipated headwind from foreign exchange.

BD (Becton, Dickinson and Company) has introduced its Scientific Advisory Board (SAB), comprising leading experts in health care, science, and technology. The board will provide insights on BD's innovation pipeline, technology capabilities, and emerging trends in the medical field. CEO Tom Polen stated that the SAB aims to enhance patient outcomes and drive growth through impactful innovations. Notable members include John DeFord from Purdue University and Claire Fraser from the University of Maryland. This strategic move is part of BD's commitment to lead in advancing health care technologies.

BD (Becton, Dickinson and Company) will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 12:00 p.m. Pacific Time. Investors can access the live webcast from BD's investor relations website, with a replay available post-event. BD, a leading global medical technology firm, is dedicated to advancing health through innovative technology and solutions, supporting healthcare providers and improving patient outcomes. BD boasts a workforce of 75,000 and operates globally to address significant health challenges.

BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, set to be paid on June 30, 2022. Shareholders on record by June 9, 2022 will receive this payment, resulting in an annual dividend rate of $3.48 per share. This decision reflects the company's commitment to return value to its shareholders while maintaining a strong presence in global medical technology.

BD (Becton, Dickinson and Company) (NYSE: BDX) announced the launch of BD Horizon RealYellow™ 586 Reagents, a breakthrough in flow cytometry developed using novel dye technology and AI guidance. These reagents enable improved data resolution, facilitating deeper biological insights in oncology, autoimmune disorders, and infectious diseases. The reagents support both conventional and spectral flow cytometry, allowing researchers to analyze more markers per sample. With their global availability, BD aims to enhance research capabilities and accelerate drug development.

BD (Becton, Dickinson and Company) has established the Sustainable Medical Technology Institute to enhance its environmental sustainability efforts. This initiative targets three key areas: sustainable product design, sterilization technologies, and materials of concern. By leveraging interdisciplinary expertise, BD aims to reduce the environmental impact of its products while supporting its 2030+ environmental, social, and governance (ESG) commitments. The institute will collaborate globally and set environmental criteria for new products to better meet sustainability needs.

BD (Becton, Dickinson and Company) will report its financial results for the second quarter of fiscal year 2022 on May 5, 2022, at approximately 6:30 a.m. ET. The announcement will include summary financial information for the quarter ending March 31, 2022. Management will conduct a conference call at 8 a.m. ET on the same day to discuss results and operational strategy.

Investors can access the news release and presentation materials on the company’s investor relations website.

BD (Becton, Dickinson and Company) has successfully completed its spinoff of Embecta Corp, which now operates independently, focusing on diabetes care. Shareholders received one share of Embecta for every five shares of BD held as of March 22, 2022. This strategic move aligns with BD's 2025 plan to enhance long-term shareholder value by allowing both companies to concentrate on their core businesses. Embecta aims to further develop diabetes injection devices, while BD continues to lead in medical and life sciences sectors.